Holen Sie sich die Stockscreener-App
2.80
1.75%
-0.05
Schlusskurs vom Vortag:
$2.85
Offen:
$2.64
24-Stunden-Volumen:
75,942
Relative Volume:
0.89
Marktkapitalisierung:
$41.99M
Einnahmen:
$130.00K
Nettoeinkommen (Verlust:
$-21.29M
KGV:
-1.4163
EPS:
-1.977
Netto-Cashflow:
$-18.29M
1W Leistung:
+16.67%
1M Leistung:
+33.97%
6M Leistung:
+53.01%
1J Leistung:
-49.09%
1-Tages-Spanne:
$2.64
$2.88
1-Wochen-Bereich:
$2.31
$2.88
52-Wochen-Spanne:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Firmenname
Serina Therapeutics Inc
Sektor
Branche
Telefon
(256) 327-9630
Adresse
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
2.80 | 42.29M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-14 | Eingeleitet | H.C. Wainwright | Buy |
Serina Therapeutics Inc Aktie (SER) Neueste Nachrichten
Serina Therapeutics Q2 Results: EPS Misses Estimate, Sales Flat - scanx.trade
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Serina Therapeutics Inc (SER) Stock News Today - tradingkey.com
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SER|Serina Therapeutics Inc|Price:1.990|Chg%:-0.080 - TradingKey
Serina Therapeutics to present at BTIG Virtual Biotechnology Conference July 28-29, 2026 - Pluang
Serina Therapeutics, Inc. Amended CEO Employment Agreement and SEC Filing Details – July 2026 - Minichart
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Serina Sets July 29 Virtual Investor Meetings at BTIG Event - Stock Titan
Form 4 Serina Therapeutics Inc For: 23 July By Investing.com - Investing.com Canada
Serina Therapeutics director Simon Farrell files initial beneficial ownership statement - Bitget
Director Simon Farrell awarded 30,500 options at Serina (SER) - Stock Titan
Serina Therapeutics, Inc. (SER) director Simon Farrell files Form 3 - Stock Titan
Serina Therapeutics Amends CEO Employment and Compensation Terms - TipRanks
Serina names Steve Ledger in amended CEO employment agreement - TradingView
Serina’s Parkinson’s trial doses all 8 first-cohort patients - Stock Titan
Serina Completes Enrollment, Dosing in First Cohort of Phase 1b Trial in Parkinson's Disease - Yahoo Finance
Serina Therapeutics Appoints Farrell Simon To Its Board Of Directors - TradingView
Serina Therapeutics Adds Industry Veteran to Board - TipRanks
Serina Therapeutics appoints Farrell Simon to Board, joins Audit and Compensation Committees - TradingView
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - GlobeNewswire
Form 13D/A SERINA THERAPEUTICS For: 22 July By Investing.com - Investing.com Nigeria
Juvenescence group reports 27.3% Serina Therapeutics (SER) beneficial stake - Stock Titan
Serina Therapeutics appoints Dr. Farrell Simon to its Board - scanx.trade
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises 7.58%Financial Data - dars.gov.et
Serina Therapeutics (SER) Q1 2026 Earnings: EPS Miss Exceeds 30% as Clinical-Stage Firm Ramps R&D SpendGuidance Upgrade Report - dars.gov.et
SER Q1 2026 Earnings: Wider-Than-Expected Loss as Biotech Pipeline AdvancesEarnings Growth Forecast - po-news-eg.net
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesMid-Term Outlook - dars.gov.et
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease - Taiwan News
Serina Therapeutics director Brannan buys $2,029 in stock - Investing.com UK
Insider Buying: Stephen Brannan Acquires Shares of Serina Therap - GuruFocus
Serina Therapeutics director Brannan buys $2,029 in stock By Investing.com - Investing.com South Africa
Serina Therapeutics, Inc. Completes Sentinel Dosing In Cohort 1 Of Phase 1b Registrational Trial Of SER-252 For Advanced Parkinson?s Disease - marketscreener.com
Form 4 Serina Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease - marketscreener.com
Serina Therapeutics advances Phase 1b trial of ... - Pluang
Serina Therapeutics Announces Completion of Sentinel Dosing - GlobeNewswire
Director Stephen K. Brannan buys 1,000 Serina Therapeutics (SER) shares at $2.03 - Stock Titan
Finanzdaten der Serina Therapeutics Inc-Aktie (SER)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
Kapitalisierung:
|
Volumen (24h):